7 nominees · 5 ballot items.
Shareholders will vote to elect seven directors; ratify Ernst & Young LLP as independent auditors for fiscal 2026; approve, on an advisory basis, executive compensation (say-on-pay); indicate the preferred frequency (one year/two years/three years) for future advisory say-on-pay votes (board recommends one year); and approve an amendment to increase the share reserve under the Amended and Restated Proto Labs, Inc. 2022 Long-Term Incentive Plan by 395,000 shares.
Elect seven directors to hold office until the next annual meeting or until their successors are duly elected.
Ratify the Audit Committee’s selection of Ernst & Young LLP as the company’s independent registered public accounting firm for fiscal 2026.
Advisory, non-binding vote to approve the compensation disclosed for the named executive officers in the Proxy Statement.
This advisory (non-binding) proposal asks shareholders to approve the Company’s named executive officer compensation as disclosed in the proxy, encompassing the Compensation Discussion and Analysis and related tables. Management seeks this approval to confirm shareholder support for its pay-for-performance program that emphasizes at-risk compensation (significant equity and incentive components) and to maintain alignment between management incentives and long-term shareholder value. The proposal comes in the context of recent executive transitions (a new CEO appointed in May 2025) and substantial equity and incentive awards in 2025, including performance stock units tied to three-year relative TSR and one-time inducement PSUs for the new CEO. The Board recommends a “FOR” vote, citing strong governance features (double-trigger change-in-control protections, minimum vesting periods, clawback policies, stock ownership guidelines) and the Compensation and Talent Committee’s view that compensation is market-competitive and aligned with performance. Management notes the 2025 pay outcomes (e.g., short-term incentive payout ~99% of target, 2023 PSUs paid at 200% due to TSR outperformance) as evidence of pay tied to performance. The Board also commits to consider shareholder feedback from the advisory vote in future compensation design decisions, making the vote an important governance signal even though it is non-binding. A “FOR” vote would endorse management’s approach; a “against” vote would signal shareholder concern and likely prompt engagement and potential program adjustments. From an analyst perspective, the key evaluation points are the mix of cash vs equity, the PSU metrics (relative TSR versus Russell 2000 Growth), use of inducement awards during CEO transition, and governance safeguards that moderate downside/upside outcomes for shareholders.
Advisory (non-binding) vote where shareholders choose whether future advisory say-on-pay votes should occur every one, two, or three years; the Board recommends a one-year (annual) frequency.
This advisory proposal asks shareholders to select the preferred interval (one, two or three years) for future advisory say-on-pay votes. The Board recommends an annual (one-year) frequency, arguing that yearly votes provide shareholders with regular, timely opportunities to express views on executive compensation and help inform the Compensation and Talent Committee’s decisions. Management’s rationale emphasizes ongoing shareholder engagement, responsiveness to changes in compensation programs or corporate circumstances, and alignment with governance best practices. From a governance perspective, annual votes increase the cadence of shareholder feedback but can raise administrative costs and may lead to more frequent short-term signaling rather than long-term assessment. The committee clarifies the outcome is non-binding; it will consider the plurality result when setting future practice but retains discretion. Analysts evaluating this proposal should weigh the benefits of frequent engagement against the potential for short-termism, and consider company-specific factors — e.g., recent CEO transition and active use of performance-based PSUs — that may support more frequent shareholder input. The Board’s recommendation for an annual vote signals a preference for sustained, iterative dialogue with investors on pay matters.
Approve an amendment to increase the number of shares available for issuance under the Amended and Restated 2022 Long-Term Incentive Plan by 395,000 shares.
This management proposal asks shareholders to approve an amendment increasing the Restated 2022 Long-Term Incentive Plan’s share reserve by 395,000 shares (raising the maximum shares available and the shares available for future grants). Management and the Compensation and Talent Committee contend the increase is prudent long-term planning to ensure sufficient capacity to grant equity awards for retention, recruitment and alignment of employees and directors, avoiding sudden cash compensation alternatives that could be costlier or less aligned with shareholder returns. The proposal is presented with governance safeguards in the Plan — e.g., no repricing of underwater options without shareholder approval, minimum vesting periods, no evergreen provision, annual limits for non-employee directors, and clawback provisions — which management cites to mitigate dilution risks. The Board frames the request as necessary to satisfy NYSE shareholder approval requirements and Code Section 422 rules for incentive stock options. In making an assessment, analysts should consider the company’s historical burn rate, current share runway (782,124 shares available as of March 1, 2026), planned hiring and retention needs, recent equity usage (including inducement PSUs for the new CEO), and potential dilution impact (current outstanding full-value awards and options). A “FOR” vote supports management’s ability to continue market-competitive equity grant practices; a “AGAINST” vote would constrain the company’s equity program and could necessitate alternative compensation strategies or more frequent requests to shareholders.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | DISCIPLINED GROWTH INVESTORS INC /MN | 10.50% | 2,497,355 | $142M |
| 2 | BlackRock, Inc. | 10.46% | 2,488,836 | $142M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6.47% | 1,538,530 | $88M |
| 4 | DIMENSIONAL FUND ADVISORS LP | 5.11% | 1,215,211 | $69M |
| 5 | STATE STREET CORP | 4.59% | 1,092,000 | $62M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.37% | 1,039,741 | $59M |
| 7 | BlackRock, Inc. | 3.26% | 774,881 | $44M |
| 8 | AMERICAN CAPITAL MANAGEMENT INC | 2.64% | 627,705 | $36M |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 2.19% | 520,251 | $30M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2.09% | 496,309 | $28M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.